Acetylon Pharmaceuticals Inc., of Boston, presented an update from ongoing phase Ib studies, showing that HDAC inhibitor ricolinostat (ACY-1215) continued to demonstrate promising activity and tolerability in combination with Revlimid (lenalidomide, Celgene Corp.) or Velcade (bortezomib, Millennium: The Takeda Oncology Co.) in relapsed or refractory multiple myeloma.